Skip to Content

Antibodies, Volume 7, Issue 2

2018 June - 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

  • Article
  • Open Access
41 Citations
12,924 Views
10 Pages

Therapeutic antibodies have shifted the paradigm of disease treatments from small molecules to biologics, especially in cancer therapy. Despite the increasing number of antibody candidates, much remains unknown about the antibody and how its various...

(This article belongs to the Collection Computational Antibody and Antigen Design)
  • Review
  • Open Access
84 Citations
20,713 Views
18 Pages

The development of anti-drug antibodies (ADAs) following administration of biotherapeutics to patients is a vexing problem that is attracting increasing attention from pharmaceutical and biotechnology companies. This serious clinical problem is also...

  • Review
  • Open Access
55 Citations
39,039 Views
20 Pages

IgG Antibody 3D Structures and Dynamics

  • Jacob White Jay,
  • Brinkley Bray,
  • Yaozhi Qi,
  • Eseosaserea Igbinigie and ,
  • Hao Wu,
  • Jinping Li and
  • Gang Ren
  • + 2 authors+ 0 author

19 April 2018

Antibodies are vital for human health because of their ability to function as nature’s drugs by protecting the body from infection. In recent decades, antibodies have been used as pharmaceutics for targeted therapy in patients with cancer, auto...

  • Review
  • Open Access
92 Citations
19,831 Views
19 Pages

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

  • Mahendra P. Deonarain,
  • Gokhan Yahioglu,
  • Ioanna Stamati,
  • Anja Pomowski and ,
  • James Clarke,
  • Bryan M. Edwards,
  • Soraya Diez-Posada and
  • Ashleigh C. Stewart
  • + 3 authors+ 0 author

31 March 2018

Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there ar...

(This article belongs to the Special Issue Antibody Drug Conjugates)
  • Article
  • Open Access
44 Citations
13,159 Views
13 Pages

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

  • Tero Satomaa,
  • Henna Pynnönen,
  • Anja Vilkman,
  • Titta Kotiranta and ,
  • Virve Pitkänen,
  • Annamari Heiskanen,
  • Bram Herpers,
  • Leo S. Price,
  • Jari Helin and
  • Juhani Saarinen
  • + 5 authors+ 0 author

22 March 2018

Antibody-drug conjugates (ADCs) offer a combination of antibody therapy and specific delivery of potent small-molecule payloads to target cells. The properties of the ADC molecule are determined by the balance of its components. The efficacy of the p...

(This article belongs to the Special Issue Antibody Drug Conjugates)
XFacebookLinkedIn
Antibodies - ISSN 2073-4468